Elahere secures full approval from FDA for types of ovarian cancer
The FDA granted accelerated approval for the drug back in November 2022, and granted priority review in December 2023.
The FDA granted accelerated approval for the drug back in November 2022, and granted priority review in December 2023.
What's Your Reaction?
